Tara Masterson

1.5k total citations · 1 hit paper
42 papers, 663 citations indexed

About

Tara Masterson is a scholar working on Hematology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Tara Masterson has authored 42 papers receiving a total of 663 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Hematology, 27 papers in Oncology and 24 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Tara Masterson's work include Multiple Myeloma Research and Treatments (34 papers), Monoclonal and Polyclonal Antibodies Research (24 papers) and Peptidase Inhibition and Analysis (14 papers). Tara Masterson is often cited by papers focused on Multiple Myeloma Research and Treatments (34 papers), Monoclonal and Polyclonal Antibodies Research (24 papers) and Peptidase Inhibition and Analysis (14 papers). Tara Masterson collaborates with scholars based in United States, Spain and Netherlands. Tara Masterson's co-authors include María‐Victoria Mateos, Ajai Chari, Philippe Moreau, Niels W.C.J. van de Donk, Jaszianne Tolbert, Thomas Renaud, Jesús F. San Miguel, Christoph Heuck, Brandi Hilder and Xiang Qin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Tara Masterson

38 papers receiving 642 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

2024 51 citations Paula Rodríguez‐Otero, Niels W.C.J. van de Donk et al. Blood Cancer Journal profile →

Peers

Countries citing papers authored by Tara Masterson

Since Specialization

Citations

This map shows the geographic impact of Tara Masterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tara Masterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tara Masterson more than expected).

Fields of papers citing papers by Tara Masterson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tara Masterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tara Masterson. The network helps show where Tara Masterson may publish in the future.

Co-authorship network of co-authors of Tara Masterson

This figure shows the co-authorship network connecting the top 25 collaborators of Tara Masterson. A scholar is included among the top collaborators of Tara Masterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tara Masterson. Tara Masterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Leo Rasche, Carolina Schinke, Cyrille Touzeau, Monique C. Minnema, (unknown), Paula Rodríguez‐Otero, María-Victoria Mateos, (unknown), Deeksha Vishwamitra, Indrajeet Singh, Xiang Qin, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Ajai Chari	5
2	P-098 Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Carolina Schinke, Cyrille Touzeau, Monique C. Minnema, Niels W.C.J. van de Donk, Paula Rodríguez‐Otero, (unknown), Leo Rasche, Deeksha Vishwamitra, Indrajeet Singh, Xiang Qin, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Ajai Chari	0
3	MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Leo Rasche, Carolina Schinke, Cyrille Touzeau, Monique C. Minnema, (unknown), Paula Rodríguez‐Otero, María‐Victoria Mateos, (unknown), Deeksha Vishwamitra, Indrajeet Singh, Xiang Qin, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Ajai Chari	9
4	P-077 Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome in Patients Receiving Talquetamab for Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Carolina Schinke, Ravi Vij, Sundar Jagannath, Larysa Sanchez, Matthew J. Pianko, Andrzej Jakubowiak, Tara Masterson, Michela Campagna, (unknown), Kathleen Gray, Thomas Renaud, Bonnie Lau, Gareth J. Morgan	2
5	Evaluation of Drug–Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model 2024 ·Targeted Oncology ·(unknown), (unknown), Brandi Hilder, Tara Masterson, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Loeckie De Zwart, Suzette Girgis, Xuewen Ma, Danièle Ouellet	1
6	GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review breakdown → 2024 ·Blood Cancer Journal ·Paula Rodríguez‐Otero, Niels W.C.J. van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar J. Bahlis, Ajai Chari	51
7	Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody 2024 ·Blood ·Ajay K. Nooka, Hira Mian, Cindy Lee, Paula Rodríguez‐Otero, Shaji Kumar, Hermann Einsele, Deeksha Vishwamitra, Diego Vieyra, Colleen Kane, Michele Kosh, Tara Masterson, Christoph Heuck, Ankit Kansagra, Philippe Moreau	0
8	Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Ajai Chari, Amrita Krishnan, Leo Rasche, Jing Christine Ye, Alfred L. Garfall, Rakesh Popat, Brea Lipe, Xiang Qin, Michela Campagna, Tara Masterson, (unknown), Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, (unknown), Kathleen Gray, Colleen Kane, Christoph Heuck, Niels W.C.J. van de Donk	19
9	Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review 2024 ·Blood Cancer Journal ·Paula Rodríguez‐Otero, Niels W.C.J. van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar J. Bahlis, Ajai Chari	2
10	P-023 Talquetamab, a G protein–coupled receptor family C group 5 member D × CD3 bispecific antibody, in relapsed/refractory multiple myeloma: efficacy and safety of patient subgroups from monumenTAL-1 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Amrita Krishnan, Luciano J. Costa, Carolina Schinke, Lionel Karlin, Daniel Morillo, Carmen Martínez‐Chamorro, Jing Christine Ye, Ajai Chari, Philippe Moreau, (unknown), Andrzej Jakubowiak, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, (unknown), Christoph Heuck, Monique C. Minnema	5
11	Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study 2023 ·Blood ·Ajai Chari, Albert Oriol, Amrita Krishnan, (unknown), Luciano J. Costa, María‐Victoria Mateos, Monique C. Minnema, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, (unknown), (unknown), Paula Rodríguez‐Otero	29
12	Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma 2021 ·ClinicoEconomics and Outcomes Research ·(unknown), (unknown), (unknown), Tara Masterson, Christoph Heuck, Annette Lam, E De Cock	15
13	Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results 2020 ·Journal of Cancer Research and Clinical Oncology ·Saad Z. Usmani, María‐Victoria Mateos, Vânia Hungria, Shinsuke Iida, Nizar J. Bahlis, Hareth Nahi, Hila Magen, Michèle Cavo, Cyrille Hulin, Darrell White, Valerio De Stefano, John Fastenau, (unknown), Christoph Heuck, Xiang Qin, Huiling Pei, Tara Masterson, Kristen Lantz, Katharine S. Gries	20
14	Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO) 2020 ·Haematologica ·Jesús F. San Miguel, Saad Z. Usmani, María‐Victoria Mateos, Niels W.C.J. van de Donk, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Kevin Liu, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, (unknown), Hareth Nahi, Ajai Chari	25
15	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma 2019 ·Blood ·Saad Z. Usmani, Hareth Nahi, María‐Victoria Mateos, Niels W.C.J. van de Donk, Ajai Chari, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Kevin Liu, Jesús F. San Miguel	80
16	SAT0066 The long noncoding rna (LNCRNA) hottip is a master regulator of cell cycle in hand synovial fibroblasts in arthritis 2018 ·Annals of the Rheumatic Diseases ·Mojca Frank‐Bertoncelj, Tara Masterson, Emmanuel Karouzakis, Christoph Kolling, Andrew Filer, Christopher D. Buckley, (unknown), Oliver Distler, Caroline Ospelt	2
17	Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs 2016 ·Veterinary Immunology and Immunopathology ·John R. Yannelli, (unknown), Tara Masterson, (unknown), Donald A. Cohen	13
18	Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy 2015 ·The Journal of Rheumatology ·Mark C. Genovese, Elizabeth C. Hsia, Stanley M. Belkowski, Caly Chien, Tara Masterson, Robin L. Thurmond, Carl L. Manthey, Xiaoyu Yan, Tingting Ge, (unknown), Andrew Greenspan	49
19	Abstract CT320: An open-label, multicenter, phase Ib study of daratumumab in combination with backbone regimens in patients with multiple myeloma 2015 ·Cancer Research ·Raymond L. Comenzo, Philippe Moreau, María‐Victoria Mateos, Joan Bladé, Lotfi Benboubker, Javier de la Rubia, Thierry Façon, Joseph W. Fay, Xiang Qin, Tara Masterson, Jordan M. Schecter, Tahamtan Ahmadi, Jesús F. San Miguel	11
20	Pharmacokinetics and Safety of Golimumab in Healthy Chinese Subjects Following a Single Subcutaneous Administration in a Randomized Phase I Trial 2013 ·Clinical Drug Investigation ·Yanli Zhuang, (unknown), Yuan Lv, Zhenhua Xu, Esther Bouman‐Thio, Tara Masterson, Joyce Ford, (unknown), Kevin J. Petty, Hugh M. Davis, Honghui Zhou	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact